ClinicalTrials.gg
CompletedNCT00560794Updated Jan 26, 2015Results posted

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 2 interventional study of Blinatumomab (MT103) in Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-26.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
53rd of 61
21 · median 67
Started
2008
the only one that year
Phase 2
30 of 61
10 open now
Registered
1st of 61
by date
Lead sponsor
5 of 61
Amgen Research (Munich) GmbH

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 53rd largest by enrollment, is the only one that started in 2008, is one of 30 in phase 2, and was the 1st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.

Read the detailed description

The presence of leukemia cells below the cytological detection limit (5% leukemic cells) is defined as minimal residual disease (MRD). If no MRD is detectable (\< 10\^-4 = less than 1 leukemia cell per 10\^4 bone marrow cells) a complete molecular remission is reached. In the last years a series of retrospective studies has shown that MRD in adult ALL is an independent prognostic factor as already demonstrated for childhood leukemia. Diagnostic tools for MRD are polymerase chain reaction (PCR) and/or flow cytometry. PCR analysis can detect fusion transcripts such as bcr/abl and individual clonal rearrangements of immunoglobulins (IgH) and/or T-cell receptor genes (TCR). About 25% of patients with MRD defined by rearrangement comprise a high-risk group with a 94% relapse rate within 3 years. In general for patients with MRD, who are not eligible for allogenic stem cell transplantation, curative treatment is not available. This accounts for MRD defined by the Philadelphia chromosome translocation as well as for MRD defined by rearrangement. The current study is set up to address the question of treating MRD positive ALL with the bispecific anti-cluster of differentiation (CD)19 x anti-CD3 antibody derivative blinatumomab (MT103).

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • Minimal Residual Disease
  • adult ALL
  • immunotherapeutic treatment
  • anti-CD19 bispecific antibody derivative
  • Blinatumomab
  • MT103
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • B-precursor ALL patients in complete hematological remission with molecular failure or molecular relapse starting at any time after consolidation I of front-line therapy within German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia (GMALL) standards or at any time outside GMALL standards.
  • Patients must have a molecular marker for evaluation of minimal residual disease which is either Breakpoint cluster region/gene on human chromosome #9 (Bcr/abl) at any detection level or individual rearrangements of immunoglobulin or T-cell receptor (TCR)-genes measured by an assay with a sensitivity of minimum 10\^-4: At least one individual marker at a quantitative level ≥ 10\^-4.
  • (ECOG) Performance Status \< 2
  • Ability to understand and willingness to sign a written
  • Signed and dated written informed consent is available

Exclusion criteria

Exclusion Criteria:

  • Current extra medullar involvement
  • History of or current relevant central nervous system (CNS) pathology (except migraine/headache and/or previous infiltration of cerebrospinal fluid (CSF) by ALL)
  • Current infiltration of cerebrospinal fluid by ALL
  • History of or current disease
  • stem cell transplantation within 6 weeks prior to study entry
  • Any prior allogeneic stem cell transplantation
  • Cancer chemotherapy within 4 weeks prior to study treatment (except for intrathecal prophylaxis and/or low dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, )
  • Radiotherapy within 4 weeks prior to study treatment
  • Therapy with monoclonal antibodies (Rituximab, MabCampath) within 6 weeks prior to study treatment
  • Known to immunoglobulins or to any other component of the study drug formulation
  • Presence of human anti-murine antibodies (HAMA)
  • Abnormal bone marrow, renal or hepatic function
  • Indication for a hypercoagulative state
  • History of other than ALL within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or cervix carcinoma in situ
  • Active severe infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator
  • Known infection with (HIV) or chronic infection with virus (HbsAg positive) or virus (anti-HCV positive)
  • Pregnant or nursing women
  • Women of not willing to use an effective form of during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception during participation in the study and at least three months thereafter
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m\^2/day. A dose increase to 30 μg/m\^2/day was permitted with evidence for insufficient response to blinatumomab treatment.

    Biological: Blinatumomab (MT103)

Interventions

  • Administered by continuous intravenous (CIV) over 4 weeks per cycle

    Also known as: Blinatumomab, AMG103, MT103, BLINCYTO™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment

    MRD Response is defined as: * If Philadelphia Chromosome (Ph) positive (+) or translocation (t) (4;11), response was achieved when Ph or t(4;11) was below detection limit and individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4. * If Ph and t(4;11) negative, response was achieved when individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4.

    Time frame: Within 4 treatment cycles, 24 weeks

Secondary outcomes

  1. Percentage of Participants With an MRD Response After Each Treatment Cycle

    MRD Response is defined as: * If Philadelphia Chromosome (Ph)+ or t(4;11), response was achieved when Ph or t(4;11) was below detection limit and individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4. * If Ph and t(4;11) negative, response was achieved when individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4.

    Time frame: At the end of each treatment cycle - Weeks 4, 10, 16, and 22.

  2. Time to Hematological Relapse

    The time to hematological relapse is defined as the time between start of first infusion of blinatumomab and the first result of hematological relapse. Participants without an event of hematological relapse were censored on their last available date of bone marrow aspiration/biopsy. Hematological relapse is defined as \> 5% leukemia cells in bone marrow. Time to hematological relapse was analyzed using Kaplan-Meier methods.

    Time frame: Up to the data cut-off date of 14 January 2010; maximum duration of follow-up was 564 days.

  3. Time to MRD Progression

    Time to MRD progression is defined for participants who do not show MRD response at any time during the study as the time from start of first infusion until the first result of MRD progression or hematological relapse, if no MRD progression was diagnosed before hematological relapse. For participants who showed MRD response during the study the time to MRD progression is defined as the time from the date of the first MRD response to the date of MRD relapse. Participants without an event of MRD progression were censored on the day of their last bone marrow aspiration/biopsy. Participants who received a bone marrow transplant were censored on the last day of bone marrow aspiration/biopsy before transplantation. MRD progression is defined as the increase in the MRD level by 1 log as compared to the baseline level (equal to a 10-fold increase in the number of MRD cells), and had to be confirmed within 6 weeks.

    Time frame: Up to the data cut-off date of 14 January 2010; Median follow-up time was 155 days

  4. Time to MRD Relapse

    Time to MRD relapse is defined only for participants with an MRD response during the study, defined as the time between the date of the first MRD response and the date of MRD relapse. If a participant experienced hematological relapse without having shown MRD positivity before then the time point of MRD relapse is defined as the time point of hematological relapse. Participants without an event of MRD relapse or hematological relapse were censored on the day of their last available bone marrow aspiration/biopsy. If a participant received a bone marrow transplant the last day of bone marrow aspiration/biopsy before transplantation was used as time point for censoring. MRD relapse is defined as reappearance of bcr/abl, and/or t(4;11) translocation at any detection level, and/or by individual rearrangements of immunoglobulin or T-cell receptor genes ≥10\^-4 for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4 and should be confirmed within 6 weeks.

    Time frame: Up to the data cut-off date of 14 January 2010; Median follow-up time was 116.5 days

  5. Number of Participants With Adverse Events

    The severity (or intensity) of AEs was evaluated according to the grading scale provided in the Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, or according to the following: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. A serious adverse event (SAE) is any untoward medical occurrence or effect that, at any dose results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. In addition, all laboratory abnormalities of grade four severity that occur during or after administration of the investigational drug, any overdose and a pregnancy or fathering were reported as SAEs.

    Time frame: From the start of study treatment until up to 4 weeks after the end of study treatment. The median treatment duration was 87.3 days.

  6. Change From Screening Value in B-cell Count During Cycle 1

    B-cells were measured by flow cytometry.

    Time frame: At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.

  7. Change From Screening Value in T-cell Count During Cycle 1

    T-cells were measured by flow cytometry.

    Time frame: At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.

  8. Serum Cytokine Peak Levels in Cycle 1

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using fluorescence-activated cell sorter (FACS)-based cytometric bead array (CBA) system.The limit of detection (LOD) for the cytokine determination was 20 pg/mL, the limit of quantification (LOQ) was 125 pg/mL.

    Time frame: Cycle 1 at pre-dose and at post infusion start at 45 minutes; 2, 6, 12, 24, and 48 hours; 7, 14, 21, and 28 days.

  9. Serum Blinatumomab Concentration at Steady State

    The mean serum concentration of blinatumomab during cycle 1. The LOQ of the assay was 100 pg/mL, and the limit of detection (LOD) was 3 pg/mL.

    Time frame: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.

  10. Area Under the Drug Concentration-time Curve From Time Zero to Infinity

    Time frame: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.

  11. Apparent Volume of Distribution

    Time frame: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.

  12. Clearance of Blinatumomab

    Time frame: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.

  13. Terminal Half-life of Blinatumomab

    Time frame: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.

07

Results

Posted Jan 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneBlinatumomab
Started21
Completed 1 treatment cycle20
Completed10
Not completed11
Withdrew: Adverse event2
Withdrew: Patient was not compliant1
Withdrew: Minimal residual disease relapse1
Withdrew: Hematological relapse1
Withdrew: Received bone marrow transplant6

Outcome measures

PrimaryPercentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment

MRD Response is defined as: * If Philadelphia Chromosome (Ph) positive (+) or translocation (t) (4;11), response was achieved when Ph or t(4;11) was below detection limit and individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4. * If Ph and t(4;11) negative, response was achieved when individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4.

Time frame:
Within 4 treatment cycles, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment80.0 (56.3 to 94.3)
Statistical analysis
  • Blinatumomab · 1-sided exact binomial test · p = 0.0000 (The null hypothesis stated that the true MRD response probability (π) ≤ 5%.)
SecondaryPercentage of Participants With an MRD Response After Each Treatment Cycle

MRD Response is defined as: * If Philadelphia Chromosome (Ph)+ or t(4;11), response was achieved when Ph or t(4;11) was below detection limit and individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4. * If Ph and t(4;11) negative, response was achieved when individual rearrangements of immunoglobulin or T-cell receptor genes are below 10\^-4.

Time frame:
At the end of each treatment cycle - Weeks 4, 10, 16, and 22.
Reported as:
Number · percentage of participants
Percentage of Participants With an MRD Response After Each Treatment Cycle
percentage of participantsBlinatumomab
MRD negativity achieved after cycle 180.0 (56.3 to 94.3)
MRD negativity achieved after cycle 280.0 (56.3 to 94.3)
MRD negativity achieved after cycle 380.0 (56.3 to 94.3)
MRD negativity achieved after cycle 480.0 (56.3 to 94.3)
SecondaryTime to Hematological Relapse

The time to hematological relapse is defined as the time between start of first infusion of blinatumomab and the first result of hematological relapse. Participants without an event of hematological relapse were censored on their last available date of bone marrow aspiration/biopsy. Hematological relapse is defined as \> 5% leukemia cells in bone marrow. Time to hematological relapse was analyzed using Kaplan-Meier methods.

Time frame:
Up to the data cut-off date of 14 January 2010; maximum duration of follow-up was 564 days.
Reported as:
Median · days
Time to Hematological Relapse
daysBlinatumomab
Time to Hematological RelapseNA (NA to NA)
SecondaryTime to MRD Progression

Time to MRD progression is defined for participants who do not show MRD response at any time during the study as the time from start of first infusion until the first result of MRD progression or hematological relapse, if no MRD progression was diagnosed before hematological relapse. For participants who showed MRD response during the study the time to MRD progression is defined as the time from the date of the first MRD response to the date of MRD relapse. Participants without an event of MRD progression were censored on the day of their last bone marrow aspiration/biopsy. Participants who received a bone marrow transplant were censored on the last day of bone marrow aspiration/biopsy before transplantation. MRD progression is defined as the increase in the MRD level by 1 log as compared to the baseline level (equal to a 10-fold increase in the number of MRD cells), and had to be confirmed within 6 weeks.

Time frame:
Up to the data cut-off date of 14 January 2010; Median follow-up time was 155 days
Reported as:
Median · days
Time to MRD Progression
daysBlinatumomab
Time to MRD Progression221.0 (170.0 to NA)
SecondaryTime to MRD Relapse

Time to MRD relapse is defined only for participants with an MRD response during the study, defined as the time between the date of the first MRD response and the date of MRD relapse. If a participant experienced hematological relapse without having shown MRD positivity before then the time point of MRD relapse is defined as the time point of hematological relapse. Participants without an event of MRD relapse or hematological relapse were censored on the day of their last available bone marrow aspiration/biopsy. If a participant received a bone marrow transplant the last day of bone marrow aspiration/biopsy before transplantation was used as time point for censoring. MRD relapse is defined as reappearance of bcr/abl, and/or t(4;11) translocation at any detection level, and/or by individual rearrangements of immunoglobulin or T-cell receptor genes ≥10\^-4 for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4 and should be confirmed within 6 weeks.

Time frame:
Up to the data cut-off date of 14 January 2010; Median follow-up time was 116.5 days
Reported as:
Median · days
Time to MRD Relapse
daysBlinatumomab
Time to MRD RelapseNA (NA to NA)
SecondaryNumber of Participants With Adverse Events

The severity (or intensity) of AEs was evaluated according to the grading scale provided in the Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, or according to the following: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. A serious adverse event (SAE) is any untoward medical occurrence or effect that, at any dose results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. In addition, all laboratory abnormalities of grade four severity that occur during or after administration of the investigational drug, any overdose and a pregnancy or fathering were reported as SAEs.

Time frame:
From the start of study treatment until up to 4 weeks after the end of study treatment. The median treatment duration was 87.3 days.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsBlinatumomab
Any adverse event21
Adverse events of at least CTC grade 317
Treatment-related adverse events21
Related adverse events of at least CTC grade 313
Serious adverse evets10
Related serious adverse events9
AEs leading to discontinuation of blinatumomab1
AEs leading to death0
SecondaryChange From Screening Value in B-cell Count During Cycle 1

B-cells were measured by flow cytometry.

Time frame:
At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
Reported as:
Mean · cells/μL
Change From Screening Value in B-cell Count During Cycle 1
cells/μLBlinatumomab
Start of infusion (N=19)0.0181 ± 0.0803
45 minutes (N=19)-0.0098 ± 0.0402
2 hours (N=18)-0.0361 ± 0.0621
6 hours (N=19)-0.0435 ± 0.0685
12 hours (N=16)-0.0417 ± 0.0689
24 hours (N=18)-0.0403 ± 0.0700
Day 2 (N=17)-0.0310 ± 0.0589
Day 7 (N=18)-0.0462 ± 0.0717
Day 14 (N=18)-0.0490 ± 0.0745
Day 21 (N=18)-0.0494 ± 0.0747
Day 28 (N=17)-0.0392 ± 0.0634
Day 35 (N=18)-0.0493 ± 0.0748
SecondaryChange From Screening Value in T-cell Count During Cycle 1

T-cells were measured by flow cytometry.

Time frame:
At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
Reported as:
Mean · cells/μL
Change From Screening Value in T-cell Count During Cycle 1
cells/μLBlinatumomab
Start of infusion (N=19)-0.0418 ± 0.2925
45 minutes (N=19)-0.3208 ± 0.3137
2 hours (N=18)-0.4976 ± 0.3454
6 hours (N=19)-0.5227 ± 0.3432
12 hours (N=16)-0.5390 ± 0.3649
24 hours (N=18)-0.4780 ± 0.3774
Day 2 (N=17)-0.3328 ± 0.3704
Day 7 (N=18)0.1231 ± 0.3051
Day 14 (N=18)0.1172 ± 0.4671
Day 21 (N=18)0.1975 ± 0.5596
Day 28 (N=17)0.1687 ± 0.3119
Day 35 (N=18)0.2271 ± 0.3739
SecondarySerum Cytokine Peak Levels in Cycle 1

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using fluorescence-activated cell sorter (FACS)-based cytometric bead array (CBA) system.The limit of detection (LOD) for the cytokine determination was 20 pg/mL, the limit of quantification (LOQ) was 125 pg/mL.

Time frame:
Cycle 1 at pre-dose and at post infusion start at 45 minutes; 2, 6, 12, 24, and 48 hours; 7, 14, 21, and 28 days.
Reported as:
Mean · pg/mL
Serum Cytokine Peak Levels in Cycle 1
pg/mLBlinatumomab
IL-2NA ± NA
IL-4NA ± NA
IL-6693.2 ± 1122.9
IL-8NA ± NA
IL-101135.3 ± 1155.6
IFN-γ408.5 ± 614.3
TNF-αNA ± NA
SecondarySerum Blinatumomab Concentration at Steady State

The mean serum concentration of blinatumomab during cycle 1. The LOQ of the assay was 100 pg/mL, and the limit of detection (LOD) was 3 pg/mL.

Time frame:
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
Reported as:
Mean · pg/mL
Serum Blinatumomab Concentration at Steady State
pg/mLBlinatumomab
Serum Blinatumomab Concentration at Steady State696 ± 147
SecondaryArea Under the Drug Concentration-time Curve From Time Zero to Infinity
Time frame:
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
Reported as:
Mean · hr*ng/mL
Area Under the Drug Concentration-time Curve From Time Zero to Infinity
hr*ng/mLBlinatumomab
Area Under the Drug Concentration-time Curve From Time Zero to Infinity481 ± 106
SecondaryApparent Volume of Distribution
Time frame:
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
Reported as:
Mean · L/m²
Apparent Volume of Distribution
L/m²Blinatumomab
Apparent Volume of Distribution2.00 ± 0.95
SecondaryClearance of Blinatumomab
Time frame:
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
Reported as:
Mean · L/hr/m²
Clearance of Blinatumomab
L/hr/m²Blinatumomab
Clearance of Blinatumomab0.939 ± 0.199
SecondaryTerminal Half-life of Blinatumomab
Time frame:
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
Reported as:
Mean · hours
Terminal Half-life of Blinatumomab
hoursBlinatumomab
Terminal Half-life of Blinatumomab1.47 ± 0.53

Adverse events

Collected over From the start of study treatment until up to 4 weeks after the end of study treatment. The median treatment duration was 87.3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab—10/21 (47.6%)21/21 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBlinatumomab
LymphopeniaBlood and lymphatic system disorders6/21
LeukopeniaBlood and lymphatic system disorders1/21
ThrombocytopeniaBlood and lymphatic system disorders1/21
Bacterial sepsisInfections and infestations1/21
BronchopneumoniaInfections and infestations1/21
Catheter related infectionInfections and infestations1/21
Escherichia sepsisInfections and infestations1/21
Medical device complicationInjury, poisoning and procedural complications1/21
Thrombosis in deviceInjury, poisoning and procedural complications1/21
ConvulsionNervous system disorders1/21
Most frequent other events
Showing 10 of 61
Most frequent other events
EventBlinatumomab
PyrexiaGeneral disorders21/21
Blood immunoglobulin A decreasedInvestigations14/21
Blood immunoglobulin G decreasedInvestigations13/21
Blood immunoglobulin M decreasedInvestigations10/21
HypokalaemiaMetabolism and nutrition disorders10/21
HeadacheNervous system disorders10/21
ChillsGeneral disorders9/21
FatigueGeneral disorders8/21
Oedema peripheralGeneral disorders8/21
LeukopeniaBlood and lymphatic system disorders7/21

Baseline characteristics

Full Analysis Set included all participants who received ≥ 1 infusion of blinatumomab who completed at least the first treatment cycle and for whom at least one minimal residual disease (MRD) response assessment was available.

Age, Continuous
Age, Continuous(years)Blinatumomab
Mean49.8 ± 18.3
Age, Customized
Age, Customized(participants)Blinatumomab
20-30 years3
31-40 years5
41-50 years2
51-60 years1
61-70 years7
> 70 years2
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab
Female12
Male8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Blinatumomab
Caucasian20
Genetic Alterations
Genetic Alterations(participants)Blinatumomab
bcr/abl translocation above detection limit5
t(4;11) translocation above detection limit2
Rearrangements of Ig / TCR genes only13
Rearrangements of Ig / TCR genes & translocations3
08

Study locations

6 sites
  • Universitätsklinikum Ulm
    Ulm, Baden-Württemberg 89081, Germany
  • Julius-Maximilians-Universität Würzburg
    Würzburg, Bayern 97080, Germany
  • Klinikum der J.W. Goethe Universität
    Frankfurt, Hessen 60590, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48129, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen ´01307, Germany
  • Universitätsklinikum Schleswig-Holstein im Städtischen Krankenhaus Kiel
    Kiel, Schleswig-Holstein 24116, Germany
09

References and documents

Publications

  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
  • Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gokbuget N, Klinger M. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64. No abstract available. PubMed 25192414 ↗
  • Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Bruggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16. PubMed 22592608 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Sep 2009 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2007
First posted
Nov 20, 2007
Start
Jan 2008
Primary completionActual
Sep 2009
CompletionActual
Nov 2014
Results first posted
Jan 7, 2015
Last update
Jan 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00560794
Responsible party
Sponsor
First posted
Nov 20, 2007
Start date
Jan 2008
Primary completion
Sep 2009
Completion
Nov 2014
Results posted
Jan 7, 2015
Last update
Jan 26, 2015

Study contacts

Ralf Bargou, Professor
principal investigator · Julius-Maximilians-Universität Würzburg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion